echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Efficacy and safety of IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma

    J Immunother Cancer: Efficacy and safety of IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immune checkpoint inhibitors are often used in the treatment of advanced melanoma.
    For example, CTLA4 and PD1 inhibitors are commonly used
    .


    The combination of the two can achieve an objective response rate (ORR) of approximately 58%, but grade 3/4 adverse events have also increased significantly


    Immune checkpoint inhibitors are often used in the treatment of advanced melanoma.


    The study is a single-arm phase II study, and immune checkpoint inhibitors include pembrolizumab (P), nivolumab (N), or ipilimumab (I)
    .


    The dosage used is the approved standard dosage


    The study is a single-arm phase II study, and immune checkpoint inhibitors include pembrolizumab (P), nivolumab (N), or ipilimumab (I)


    The study included 131 patients, 114 (87%) patients used pembrolizumab (pembrolizumab)


    research summary

    research summary

    In the efficacy evaluation population, ORR was 51% (including 18 CR, 27 PR), DCR was 70% (including 18 CR, 27 PR, and 17 SD), and the median DoR was 33 months; 13 previous cases The ORR of patients who received radiotherapy was 64% (including 5 cases of CR)
    .


    The median PFS was 12.


    In the efficacy evaluation population, ORR was 51% (including 18 CR, 27 PR), DCR was 70% (including 18 CR, 27 PR, and 17 SD), and the median DoR was 33 months; 13 previous cases The ORR of patients who received radiotherapy was 64% (including 5 cases of CR)


    Efficacy evaluation

    Efficacy evaluation

    The median time to response was 2.
    79 months (2.
    07, 20.
    68)
    .


    Patients who achieved complete remission (CR) or partial remission (PR) had a durable response, with a median DOR of 30.


    The median time to response was 2.


    Toxicity assessment was performed in 114 patients.


    Common adverse events

     Common adverse events

    In summary, studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future
    .

    In summary, studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future
    .


    Studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future


    Original source:

    Yousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
    Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
    J Immunother Cancer.
    2021 Jun;9(6):e002057.
    doi: 10.
    1136 /jitc-2020-002057.

    Yousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
    Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
    J Immunother Cancer.
    2021 Jun;9(6):e002057.
    doi: 10.
    1136 /jitc-2020-002057.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.